Trial record 19 of 552 for:
"Cystic Fibrosis"
Costimulatory Molecules as Biomarkers in Cystic Fibrosis
This study is currently recruiting participants.
Verified July 2011 by Oregon Health and Science University
Sponsor:
Oregon Health and Science University
Information provided by:
Oregon Health and Science University
ClinicalTrials.gov Identifier:
NCT01353950
First received: May 12, 2011
Last updated: July 19, 2011
Last verified: July 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to investigate the expression of a certain class of molecules, called costimulatory molecules, in humans with Cystic Fibrosis. Cystic Fibrosis is a genetic disorder which renders the lung susceptible to persistent inflammation which, at times, can worsen, resulting in accelerated decline in lung function and eventually death or transplant. Our goal is to determine if the levels of costimulatory markers can be used to predict exacerbation and subsequent lung function decline in subjects with Cystic Fibrosis.
| Condition |
|---|
|
Cystic Fibrosis |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Costimulatory Molecules as Biomarkers in Cystic Fibrosis |
Resource links provided by NLM:
Genetics Home Reference related topics:
cystic fibrosis
MedlinePlus related topics:
Cystic Fibrosis
U.S. FDA Resources
Further study details as provided by Oregon Health and Science University:
Biospecimen Retention: Samples Without DNA
Plasma, Serum, urine
| Estimated Enrollment: | 40 |
| Study Start Date: | July 2011 |
| Estimated Study Completion Date: | June 2013 |
| Estimated Primary Completion Date: | June 2013 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Adult Cystic Fibrosis Patients
Adults with Cystic Fibrosis will be followed longitudinally for 2 years
|
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Adults with Cystic Fibrosis
Criteria
Inclusion Criteria:
- Willingness to participate
Exclusion Criteria:
- Presence of HIV
- Presence of Lymphoma/Leukemia
- Presence of Lung or other solid organ Transplant
- Pregnancy
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01353950
Contacts
| Contact: Jeffrey A Gold, MD | 5034181496 | goldje@ohsu.edu |
Locations
| United States, Oregon | |
| Oregon health and Sciences University | Recruiting |
| Portland, Oregon, United States, 97239 | |
| Contact: Jeffrey A GOld, MD 503-418-1496 goldje@ohsu.edu | |
| Principal Investigator: Jeffrey A GOld, MD | |
Sponsors and Collaborators
Oregon Health and Science University
More Information
No publications provided
| Responsible Party: | Jeffrey A. Gold, MD, Oregon health and Sciences University |
| ClinicalTrials.gov Identifier: | NCT01353950 History of Changes |
| Other Study ID Numbers: | IRB00007132 |
| Study First Received: | May 12, 2011 |
| Last Updated: | July 19, 2011 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Oregon Health and Science University:
|
Costimulatory molecules Cystic Fibrosis Biomarkers |
Additional relevant MeSH terms:
|
Cystic Fibrosis Fibrosis Pancreatic Diseases Digestive System Diseases Lung Diseases |
Respiratory Tract Diseases Genetic Diseases, Inborn Infant, Newborn, Diseases Pathologic Processes |
ClinicalTrials.gov processed this record on June 18, 2013